arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 9/2024 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    THERAPY FROM A CRITICAL VIEWPOINT

    Discontinue beta-blockers after myocardial infarction without cardiac failure?

    NEW ON THE MARKET

    High-dose aflibercept (EYLEA) for macular degeneration/diabetic macular edema

    a-t READERS QUESTIONS AND COMMENTS

    Recommendation of the German Standing Committee on Vaccination (STIKO): meningococcal B vaccine (BEXSERO) for infants

    IN BRIEF

    Stress ulcer prophylaxis during ventilation: less bleeding, but no effect on mortality

    Unexpected pregnancies with semaglutide (OZEMPIC, WEGOVY) and tirzepatide (MOUNJARO)

    Early detection of familial hypercholesterinaemia: IQWiG favours cascade screening

    Intravenous iron: clarification by the company Vifor on FERINJECT and the competitor product MONOFER

    Multivitamins without effect on mortality

    Gender marketing: BUSCOPAN PLUS in pink
    free

    SIDE EFFECTS

    Liver damage with fezolinetant (VEOZA)

    e a-t ON THE INTERNET

    Patent thickets for original preparations hinder the market introduction of generics

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles

    Wir schätzen Ihr Feedback

    Nehmen Sie an unserer Umfrage teil!